Relay Therapeutics officer sells shares to cover taxes

Relay Therapeutics, Inc. officer Peter Rahmer, Chief Corporate Development Officer, had 748 shares of common stock sold on July 28, 2026 at $18.61 per share to cover income tax withholding from the vesting of 3,051 RSUs.

Rhea-AI Filing Summary

Relay Therapeutics, Inc. officer Peter Rahmer, Chief Corporate Development Officer, had 748 shares of common stock sold on July 28, 2026 at $18.61 per share to cover income tax withholding from the vesting of 3,051 RSUs. He had 228,165 shares remaining afterward, including 6,102 shares underlying RSUs, and no discretion over the tax-related sale, which followed the company’s RSU vesting policies.

Insider Trade Summary

Net Seller: 748 shares

Net Sell 1 txn

Insider Rahmer Peter

Role See remarks

Sold 748 shs ($14K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	748	$18.61	$14K

Holdings After Transaction: Common Stock — 228,165 shares (Direct)

Footnotes (2)

1. F1. Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,051 shares of restricted stock units ("RSUs") on July 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
2. F2. Includes 6,102 shares underlying RSUs.

Key Figures

Shares sold: 748 shares Sale price per share: $18.61 Shares following transaction: 228,165 shares +2 more

5 metrics

Shares sold 748 shares Common stock sold on July 28, 2026 to cover tax withholding

Sale price per share $18.61 Price per share for the 748 sold Relay Therapeutics common shares

Shares following transaction 228,165 shares Total beneficial ownership after the transaction, including RSU-based shares

RSUs vested 3,051 RSUs Restricted stock units vesting on July 27, 2026 that triggered tax withholding

RSU underlying shares held 6,102 shares Number of shares underlying RSUs included in post-transaction holdings

Key Terms

restricted stock units, income tax withholding obligations, vesting

3 terms

restricted stock units financial

"vesting of 3,051 shares of restricted stock units ("RSUs") on July 27, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

income tax withholding obligations financial

"Sale of shares to cover the reporting person's income tax withholding obligations"

vesting financial

"upon the vesting of 3,051 shares of restricted stock units ("RSUs")"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Relay Therapeutics (RLAY) report for Peter Rahmer?

Relay Therapeutics reported that officer Peter Rahmer had 748 shares of common stock sold at $18.61 per share on July 28, 2026. The sale covered income tax withholding on vested RSUs and followed the company’s RSU vesting policies.

Was the Relay Therapeutics (RLAY) share sale by Peter Rahmer discretionary?

The sale was not discretionary. Shares were sold to cover Rahmer’s income tax withholding obligations on the vesting of 3,051 RSUs, and the transaction was executed in accordance with Relay Therapeutics’ policies for RSU vesting.

How many Relay Therapeutics (RLAY) shares does Peter Rahmer hold after this transaction?

After the tax-related sale, Rahmer beneficially held 228,165 shares of Relay Therapeutics common stock. This total includes 6,102 shares underlying restricted stock units, as referenced in the filing’s footnotes.

What price was received for the Relay Therapeutics (RLAY) shares sold for Peter Rahmer’s taxes?

The 748 shares of Relay Therapeutics common stock associated with Peter Rahmer’s tax withholding were sold at an average price of $18.61 per share. The transaction was categorized as a sale of non-derivative common stock.

What triggered the tax-withholding share sale for Relay Therapeutics (RLAY) officer Peter Rahmer?

The sale was triggered by the vesting of 3,051 restricted stock units (RSUs) for Peter Rahmer on July 27, 2026. Shares were sold the next day solely to satisfy his related income tax withholding obligations.

Does the Relay Therapeutics (RLAY) filing mention remaining RSUs for Peter Rahmer?

Yes. The filing states Rahmer’s holdings include 6,102 shares underlying RSUs. This means a portion of his reported 228,165-share position consists of unvested or unsettled restricted stock units tied to Relay Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/30/2026 - 04:14 PM Accepted by SEC EDGAR 07/30/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rahmer Peter

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2026		S		748(1)	D	$18.61	228,165(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,051 shares of restricted stock units ("RSUs") on July 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.

2. Includes 6,102 shares underlying RSUs.

Remarks:

Cheif Corporate Development Officer

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)